Referred to the House Committee on Energy and Commerce.
This bill (Toxic-Free Beauty Act of 2025) amends the Federal Food, Drug, and Cosmetic Act to prohibit cosmetics that intentionally contain ortho-phthalates or formaldehyde-releasing preservatives, a list of specified intentionally added chemicals (15 named substances), and certain contaminants above defined thresholds (1,4-dioxane ≥2 ppm, lead ≥2 ppm for color cosmetics or ≥5 ppm for general cosmetics, and any detectable asbestos/asbestos-contaminated talc). It adds definitions for terms such as color cosmetic, contaminant, formaldehyde-releasing preservative, general cosmetic, ingredient, intentionally added, and ortho-phthalate.
Scope and justification: liberals emphasize precaution and public-health protection; conservatives emphasize need for risk-based, evidence-driven action and narrower scope.
Relative to its intended legislative type, this bill is a clear substantive statute that amends the FD&C Act to prohibit specific ingredients and set contaminant thresholds in cosmetics.
This bill (Toxic-Free Beauty Act of 2025) amends the Federal Food, Drug, and Cosmetic Act to prohibit cosmetics that intentionally contain ortho-phthalates or formaldehyde-releasing preservatives, a list of specified intentionally added chemicals (15 named substances), and certain contaminants above defined thresholds (1,4-dioxane ≥2 ppm, lead ≥2 ppm for color cosmetics or ≥5 ppm for general cosmetics, and any detectable asbestos/asbestos-contaminated talc).
It adds definitions for terms such as color cosmetic, contaminant, formaldehyde-releasing preservative, general cosmetic, ingredient, intentionally added, and ortho-phthalate.
The bill preserves state authority to restrict or require reporting about cosmetic ingredients and clarifies that the Modernization of Cosmetics Regulation Act of 2022 does not preempt state action except as stated.
By content alone, the bill is plausible to advance in the House as a consumer-safety measure but faces significant obstacles in the Senate (procedural hurdles, need for broad agreement, industry pushback). The measure’s explicit preservation of state authority and delayed effective date help its acceptability, but the relatively sweeping bans of many common ingredients and lack of implementation funding or phased compliance increase resistance and legal/technical scrutiny, lowering overall likelihood.
Relative to its intended legislative type, this bill is a clear substantive statute that amends the FD&C Act to prohibit specific ingredients and set contaminant thresholds in cosmetics. Its strengths include explicit ingredient lists with CAS numbers, added statutory definitions, and a clear effective date. Its weaknesses include absence of fiscal or resourcing provisions, limited implementation detail (testing methods, compliance pathways, exemptions/phase-in), minimal provisions addressing edge cases, and no new measurement or reporting requirements.
Scope and justification: liberals emphasize precaution and public-health protection; conservatives emphasize need for risk-based, evidence-driven action and narrower scope.
These are examples from the analysis, not a ranked list of the most-affected groups.
Scope and justification: liberals emphasize precaution and public-health protection; conservatives emphasize need for risk-based, evidence-driven action and narrower scope.
A mainstream liberal would likely view the bill favorably as a strong consumer- and public-health-oriented step to remove known or suspected toxicants from cosmetics and to protect communities disproportionately exposed to contaminated products.
They would see the explicit bans, contaminant thresholds, and retention of state authority as precautionary measures that address regulatory gaps.
They would also note the January 1, 2027 effective date as a reasonable transition window while urging adequate enforcement.
A centrist/technocratic observer would generally support the bill's public-safety goals but would be focused on implementation details, cost-benefit tradeoffs, and regulatory feasibility.
They would welcome clear prohibitions and defined contaminant thresholds, while expressing concern about the FDA's capacity, testing standards, and potential economic impacts on small businesses.
The centrist would likely seek phased implementation, clear guidance, and funding or mechanisms to reduce unintended practical burdens while keeping the consumer-protection objective intact.
A mainstream conservative would be skeptical of the bill’s new federal prohibitions as an added regulatory burden on businesses and potential driver of costs and litigation.
They would raise concerns about federal overreach into commerce, the economic impact on manufacturers (particularly small firms), and whether the bans are driven by solid, risk-based science versus precaution.
They might appreciate the preservation of state authority but would prefer a more limited, risk-based federal role and greater deference to market and scientific review processes.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
By content alone, the bill is plausible to advance in the House as a consumer-safety measure but faces significant obstacles in the Senate (procedural hurdles, need for broad agreement, industry pushback). The measure’s explicit preservation of state authority and delayed effective date help its acceptability, but the relatively sweeping bans of many common ingredients and lack of implementation funding or phased compliance increase resistance and legal/technical scrutiny, lowering overall likelihood.
The bill has not accumulated any surfaced votes yet.
Scope and justification: liberals emphasize precaution and public-health protection; conservatives emphasize need for risk-based, evidence-…
By content alone, the bill is plausible to advance in the House as a consumer-safety measure but faces significant obstacles in the Senate…
Relative to its intended legislative type, this bill is a clear substantive statute that amends the FD&C Act to prohibit specific ingredients and set contaminant thresholds in cosmetics. Its strengths include explicit i…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.